Teclistamab offers durable responses in multiple myeloma.
Treatments in multiple myeloma results in a high rate of deep and durable responses with triple class exposed relapsed or refractory multiple myeloma.
It is a T-cell redirecting bispecific antibody.
Tradename Tecvayli.
Teclistamab targets cluster of differentiation 3 (CD3) and B-cell maturation antigen (BCMA), which is found at increased levels on multiple myeloma cells.
It targets both CD3 expressed on the surface of T cells and B cell maturation antigen expressed on the surface of myeloma cells.
Data showed an overall response rate (ORR) of 65% with the recommended subcutaneous (SC) Phase II dose in a group of subjects who were heavily pre-treated with a median of five previous lines of treatment.
Subjects received 1500 µg/kg SC.
About 58% of the subjects in teclistamab arm had a very good partial response (VGPR) or better and 40% had a complete response (CR) or better.
The median duration of response was not met and 85% of the subjects were alive and receiving treatment after 7.1 months of median follow-up.
In the MajesTEC trial the overall response rate was 61.8% with a CR of 46.4% and 11.8% very good partial response with 3.6% progressive disease in refractory and relapsed myeloma.
The most common adverse events at the dose being cytokine release syndrome and neutropenia.
1500ug/kg SC.